Myelodysplastic Syndromes (MDS)
Resource Hub
Organizations and Advocacy Groups
The following organizations provide disease education, additional support, and expert opinions. This list of independent organizations is provided as an additional resource for obtaining information related to MDS and does not indicate endorsement by Bristol Myers Squibb of an organization or its communications.
Tools
Educational Resources
Acknowledgments
We would like to thank the Spotlight on Anemia Steering Committee for their continued partnership, perspectives, and commitment to patient care.
David Sallman, MD (Chair)
Moffitt Cancer Center
Namrata Chandhok, MD
Sylvester Comprehensive Cancer Center
Yunying (Erin) Chen, NP
UCLA Health
Carter Davis, MD
Ochsner Health
Rebecca Garcia Hunt, PharmD
Atrium Health Wake Forest Baptist
Zachary Hanson, MD
Loma Linda University Cancer Center
Sanjay Juneja, MD
Mary Bird Perkins Cancer Center
Sanam Loghavi, MD
University of Texas MD Anderson Cancer Center
Yazan Madanat, MD
UT Southwestern Medical Center
Neil Palmisiano, MD
Rutgers Cancer Institute of New Jersey
Samantha Salvatora, PA
University of Texas MD Anderson Cancer Center
Diagnosing MDS requires an extensive series of tests, but it is also important to have a high clinical suspicion to identify risk factors for developing MDS, such as advancing age.Hasserjian RP et al. Blood. 2023;142:2247-2257. Sekeres MA. Hematol Oncol Clin North Am. 2010;24:287-294.
Delays in treatment may result in more severe anemia, reduced quality of life, and increased mortality risk. Early treatment is essential to improve long-term outcomes.Kaka S et al. Transfus Med. 2022;32(1):3-23.
